Protocol 15-0020 targeted reduction of antibiotics using procalcitonin in a multi-center, randomized, blinded, placebo-controlled non-inferiority study of azithromycin treatment in outpatient adults…
Ended Awarded Last action
- Contract number
- HHSN27200012
- Awardee
-
Emory University UEI S352L5PJLMP8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,459,476
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (VTEU) Award Notice · Posted Mar 29, 2012
- Contract value 100% obligated
- $2,459,475.85 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Atlanta, GA 30322, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$710,056 | |
| Supplemental Agreement for work within scope | -$3 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $455,564 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $794,919 | |
| Exercise an Option | $332,423 | |
| Exercise an Option | $663,768 | |
| Exercise an Option | $334,541 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $520,509 | |
| Other Administrative Action | $0 | |
| Original award | $67,811 |
Show all 13
About this award
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to Emory University. The contract is for a study entitled "PROTOCOL 15-0020 TARGETED REDUCTION OF ANTIBIOTICS USING PROCALCITONIN IN A MULTI-CENTER, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED NON-INFERIORITY STUDY OF AZITHROMYCIN TREATMENT IN OUTPATIENT ADULTS WITH SUSPECT LOWER RESPIRATORY TRACT INFECTION (LRTI) AND A PROCALCITONIN LEVEL OF 0.1 NG/ML." This is a $2,459,475.85 cost-no-fee contract that is part of NIAID's Vaccine and Treatment Evaluation Units (VTEU) program. The contract has a period of performance through June 14, 2022 and does not have a set-aside designation.
Description
Protocol 15-0020 targeted reduction of antibiotics using procalcitonin in a multi-center, randomized, blinded, placebo-controlled non-inferiority study of azithromycin treatment in outpatient adults with suspect lower respiratory tract infection (LRTI) and a procalcitonin level of≤0.1 NG/ML.
Quick answers
Who was awarded contract HHSN27200012?
HHSN27200012 was awarded to Emory University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 14, 2016.
How much is contract HHSN27200012 worth?
The government has obligated $2,459,476 on HHSN27200012.
Is contract HHSN27200012 an order under another contract?
Yes. HHSN27200012 is a delivery order under HHSN272201300018I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200012 competed?
The extent of competition for HHSN27200012 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award